Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 14/20 | 0.54 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | PTPRC | P08575 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7623932 | 0.91 | PTPN1 (0.56) | PTPN1PTPN2LMNAHSD17B10EPHX2 | |
| SCHEMBL7621376 | 0.88 | PTPN1 (0.52) | PTPN1PTPN2LMNAHSD17B10EPHX2 | |
| SCHEMBL7624690 | 0.87 | PTPN1 (0.56) | PTPN1PTPN2LMNAHSD17B10EPHX2 | |
| SCHEMBL7165173 | 0.79 | PTPN1 (0.62) | PTPN1PTPN2EPHX2PPARG | |
| SCHEMBL6846458 | 0.78 | PTPN1 (0.59) | PTPN1PTPN2LMNAHSD17B10PTPRC | |
| SCHEMBL7622221 | 0.75 | PTPN1 (0.54) | PTPN1PTPN2LMNAHSD17B10EPHX2 | |
| SCHEMBL7620482 | 0.71 | PTPN1 (0.69) | PTPN1PTPN2EPHX2PPARG | |
| SCHEMBL5399352 | 0.71 | PTPN1 (0.46) | PTPN1PTPN2PPARGALDH1A1 | |
| SCHEMBL7161699 | 0.70 | PTPN1 (1.00) | PTPN1PTPN2PTPRC | |
| SCHEMBL7165383 | 0.70 | PTPN1 (0.59) | PTPN1PTPN2LMNAHSD17B10EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6486142-B2 | A,A-DIFLUOROBENZYLPHOSPHONIC ACID DERIVATIVES | MERCK FROSST CANADA & CO. (CA) | 2002-11-26 | — | — | US | claimed |
| US-20020058644-A1 | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | MERCK FROSST CANADA LTD. (CA) | 2002-05-16 | — | — | US | claimed |
| US-6486142-B2 | A,A-DIFLUOROBENZYLPHOSPHONIC ACID DERIVATIVES | MERCK FROSST CANADA & CO. (CA) | 2002-11-26 | — | — | US | disclosed |
| US-20020058644-A1 | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | MERCK FROSST CANADA LTD. (CA) | 2002-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058644-A1 | Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) | PPM1B, PTPRO, PTPA | PTPN1 13/4885PTPN2 32/4885LMNA 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.